Topics:

Issues Relating to Cytotoxic and Biologic Agents in Liver-Limited Disease

Issues Relating to Cytotoxic and Biologic Agents in Liver-Limited Disease

CONTINUING MEDICAL EDUCATION

Activity Release Date: August 15, 2009 Activity Expiration Date: August 15, 2010

About the Activity
This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.

Activity Learning Objectives
After reading this article, participants should be able to:

  • Appraise and assimilate the surgical issues in liver-limited disease;
  • Demonstrate an understanding of the correct usage of all chemotherapy and biologic agents for liver-limited disease;
  • Incorporate into practice knowledge of toxicity issues in liver-limited disease;
  • Develop and use a multidisciplinary team relationship (oncologist, surgeon, and radiologist) to maximize patient care

 

Target Audience
This activity targets physicians in the fields of oncology and hematology.

Accreditation
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Continuing Education Credit
AMA PRA Category 1 Credit
CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Compliance Statement

This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.

However, CME LLC, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.

Financial Disclosures
Dr. Chu serves as a consultant for Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche Inc., and ImClone Systems. Dr. Alberts receives research support from Bristol-Myers Squibb Company.

Copyright
Copyright owned by CME LLC. Copyright 2009, all rights reserved.

Contact Information
We would like to hear your comments regarding this or other activities provided by CME LLC. In addition, suggestions for future activities are welcome. Contact us at:

Director of Continuing Education
CME LLC
Harborside Financial Center
Plaza 3, Suite #806
Jersey City, NJ 07311
Phone: 800-447-4474

Issues Relating to Cytotoxic and Biologic Agents in Liver-Limited Disease
Steven R. Alberts, MD, MPH
Professor of Medicine and Pharmacology
Mayo Clinic College of Medicine
Consultant, Division of Oncology
Medical Director, Cancer Center Clinical Research Office
Rochester, Minnesota

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.